Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia

NCT02799147 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.

NCT NCT02799147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02799147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia
Lead sponsor
St. Petersburg State Pavlov Medical University
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2016
Completion date
November 30, 2020
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, leukemia, acute lymphoblastic, mixed-lineage acute leukemias